№ files_lp_3_process_9_69560
File format: docx Character count: 16716 File size: 35 KB
Shared care guideline outlining the recommended use, dosing, administration, and monitoring of stimulant and non-stimulant medications for adults diagnosed with ADHD, based on specialist initiation and NICE standards.
Year: 2026
Region: South Tyneside and Sunderland, UK
Topic: Adult Attention Deficit Hyperactivity Disorder (ADHD) treatment
Document type: Clinical guideline / Shared care protocol
Issuing body: South Tyneside and Sunderland Area Prescribing Committee
References: NICE Clinical Guideline 87, NICE Quality Standard 39
Target audience: Healthcare professionals managing adults with ADHD
Medications covered: Methylphenidate, Dexamfetamine, Lisdexamfetamine, Atomoxetine
Indications: ADHD in patients aged 18 years and over
Exclusions: Patients aged 5–17 years, patients under 5 years
Dosage forms: Tablets, capsules, oral solution
Administration instructions: Standard and modified-release regimens, including special administration for dysphagia or GI issues
Adverse effects: Appetite loss, insomnia, mood changes, cardiovascular effects, gastrointestinal effects, rare psychiatric effects
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Shared Care Guideline for Atomoxetine for the Treatment of Attention Hyperactivity Disorder (ADHD) in Children and Adolescents (Version 2.2, 17.8.2017)
Reference Number: ATOMOXETINE FOR THE TREATMENT OF ATTENTION HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
Version: 2.2
Replaces: 2.1
Issue date: 17.8.2017
Review date: 17.8.2020
Authors: Dr Prathiba Chitsabesan – Healthy Young Minds Consultant, Pennine Care NHS Foundation Trust; Arifa Raza Azmi – Clinical Pharmacist, Pennine Care NHS Foundation Trust
Approving body: Pathways and Guidelines Development Subgroup
Date approved by Pathways and Guidelines Development Subgroup: 13.7.2017
Note: Approving body Greater Manchester Medicines Management Group
Date approved by Greater Manchester Medicines Management Group: 17.8.2017
Organisation: Pennine Care NHS Foundation Trust
Region: Greater Manchester
Therapeutic area: Attention Deficit Hyperactivity Disorder (ADHD)
Medicine: Atomoxetine hydrochloride
Dosage forms: Hard capsules (10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg); 4mg/ml oral solution
Licensed population: Children and adolescents aged 6 years and above
Document type: Shared Care Guideline / Shared Care Protocol
Related documents: Summary of Product Characteristics; BNF
Indication: Severe or moderate ADHD impairment where psychological/behavioural measures alone are insufficient
Contraindications: Hypersensitivity to atomoxetine; concomitant use with MAOIs; severe cardiovascular or cerebrovascular disorders without specialist advice; narrow angle glaucoma; pheochromocytoma; hereditary fructose intolerance (oral solution)
Pregnancy and lactation status: Prescribing responsibility remains with the Specialist
Lisdexamfetamine Dimesilate - PBS Listing and Submission for Expanded Age Group
Year: 2019
Region / City: Australia
Subject: ADHD Treatment, Medication Listing
Document Type: Submission to PBAC (Pharmaceutical Benefits Advisory Committee)
Author: Shire Australia Pty Ltd
Target Audience: Healthcare professionals, policymakers
Period of Validity: Ongoing
Approval Date: 22 July 2013 (TGA registration for 30mg, 50mg, and 70mg strengths), 2017 (TGA registration for 20mg, 40mg, and 60mg strengths)
Date of Modification: 2019 (PBAC submission)
Topics: Dexamfetamine Atomoxetine Lisdexamfetamine